Northland Starts Aridis Pharmaceuticals (ARDS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Laidlaw Starts Aridis Pharmaceuticals (ARDS) at Buy
September 10, 2018 6:41 AM EDTLaidlaw analyst Francois Brisebois initiates coverage on Aridis Pharmaceuticals (NASDAQ: ARDS) with a Buy rating and a price target of $23.00.
The analyst come sout Buy rated and his target is based on SOTP analysis with AR-301 valued at $13/share, AR-105 at... More
Cantor Fitzgerald Starts Aridis Pharmaceuticals (ARDS) at Overweight
September 10, 2018 5:06 AM EDTCantor Fitzgerald analyst Louise Chen initiates coverage on Aridis Pharmaceuticals (NASDAQ: ARDS) with a Overweight rating and a price target of $25.00.
The analyst comments "ARDS is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening... More
